Geron Corporation (GERN NASDAQ) stock market data APIs
$1.2566
-0.02(-1.6%)
as of October 31, 2025
Try our APIs with
free plan!
Geron Corporation Financial Data Overview
Price chart is built with
Anychart
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Prev. Close
1.2566
Open
1.2328
High
1.2566
Low
1.2102
52 wk Range
1.09-4.5
Market Cap
804 M
Shares Outstanding
638 M
Revenue
164 M
EPS
0
Beta
0.571
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Geron Corporation (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Geron Corporation data using free add-ons & libraries
Get Geron Corporation Fundamental Data
Geron Corporation Fundamental data includes:
- Net Revenue: 164 M
- EBITDA: -76 991 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.0256
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Geron Corporation News
New
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Arcellx, Inc. (ACLX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook giv...
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Geron (GERN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a g...
GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term stockhol...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Cassava Sciences, Inc. AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
